Form 4: Roivant Sciences CFO Richard Pulik Disposes of Shares to Cover Tax Obligations

Richard Pulik, CFO of Roivant Sciences Ltd., disposed of 2,341 common shares on May 28, 2024, to cover tax withholding obligations related to the vesting and settlement of RSUs.

Summary

• On May 28, 2024, Richard Pulik, the CFO of Roivant Sciences Ltd., disposed of 2,341 common shares.
• The transaction was executed at a price of $10.83 per share.
• This disposal was a 'net settlement' by Roivant Sciences to satisfy tax withholding obligations related to the vesting and settlement of previously granted Restricted Stock Units (RSUs).
• Following the transaction, Pulik directly owns 292,701 common shares of Roivant Sciences Ltd.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing related to insider transactions. It doesn't contain any information that would significantly impact investor sentiment positively or negatively. The transaction is a standard practice for covering tax obligations.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as the CFO, ensuring fair markets.

Comparison to Industry Standards

• Similar transactions are common among executives at publicly traded companies like Roivant Sciences, such as Pfizer, Johnson & Johnson, and Novartis, where stock-based compensation is a significant part of their remuneration.
• These companies also regularly report Form 4 filings when executives dispose of shares to cover tax obligations or for other financial planning purposes.
• The scale of the transaction is typical for executives at this level, and the reporting is in line with SEC regulations.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine disposal of shares to cover tax obligations.

Key Dates